Lincoln Pharmaceuticals Limited has reported a standalone net profit of Rs. 19.01 crore for Q1 FY 2023-24 ended June 2023 as against net profit of Rs. 15.01 crore in Q1 FY 2022-23, growth of 26.66 per cent Y-o-Y. The total income for the quarter ended June 2023 was reported at Rs. 143.31 crore, higher by 10.27 per cent Y-o-Y over total income of Rs. 129.97 crore in Q1 FY 2022-23. EBITDA for Q1 FY24 was reported at Rs. 28.41 crore as compared to EBITDA of Rs. 23.41 crore in Q1 FY 2022-23, growth of 21.36 per cent Y-o-Y. EPS for Q1 FY 24 was at Rs. 9.49 per share, a company release has notified.
The company has set a target of achieving Rs. 750 crore by FY26
According to the release, the company has started selling Cephalosporin plant in domestic market as well as exporting goods. For other countries, plant inspection and product registration is under process. Apart from it, the company has also started exporting to Canada.
Mahendra Patel, Managing Director (MD), Lincoln Pharmaceuticals Limited, said in the release, “The company is progressing well on its long-term growth roadmap, and has been able to achieve profit every single year over the last 10 years. It has set a target of achieving Rs. 750 crore by FY26 while maintaining or improving its margins.”
During FY23, the company launched 18 products in the domestic market and filled over 130 dossiers in the export market. It has over 1,700 registered products and another 700 are in pipeline.
